Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease

Stopped Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.

Conditions

• Acute Respiratory Distress Syndrome
• SARS-CoV-2
• COVID
• COVID-19
• Severe Acute Respiratory Syndrome

Interventions

• DRUG: Valsartan (Diovan)
• DRUG: Placebo oral tablet

Sponsor

Radboud University Medical Center